<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823212</url>
  </required_header>
  <id_info>
    <org_study_id>S2046</org_study_id>
    <secondary_id>ACTRN12608000582358</secondary_id>
    <nct_id>NCT00823212</nct_id>
  </id_info>
  <brief_title>The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions</brief_title>
  <acronym>PLATINUM</acronym>
  <official_title>PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to Two De Novo Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™
      Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo
      atherosclerotic coronary artery lesions.

      This clinical trial compares outcomes in patients treated with PROMUS Element to those in
      patients treated with a different everolimus-eluting coronary stent. The lesions are of
      average length in average-sized vessels (&quot;workhorse&quot;). A companion sub-trial evaluates
      outcomes in smaller vessels (SV) and another sub-trial evaluates outcomes in longer lesions
      (LL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The wide-spread use of DES has evolved as standard of care in de novo lesions. The proposed
      study will evaluate the safety and effectiveness of PROMUS Element for the treatment of de
      novo atherosclerotic lesions in native coronary arteries. The study design is consistent with
      the draft guidance for industry titled, &quot;Coronary Drug-Eluting Stents - Nonclinical and
      Clinical Studies&quot; (March 2008).

      During the trial, thienopyridines must be administered according to the 2007 American College
      of Cardiology (ACC)/American Heart Association (AHA)/Society for Cardiovascular Angiography
      and Interventions (SCAI) guidelines, which recommended that clopidogrel (75 mg daily) or
      ticlopidine (250 mg twice daily) be prescribed after stent implantation for at least 6 months
      in all patients, and for at least 12 months in patients who are not at high risk of bleeding.
      For sites in the United States, the use of prasugrel is not allowed as part of the PLATINUM
      Clinical Trial. For sites in other countries, prasugrel may be prescribed according to its
      approved dosing in countries in which it is available. For patients taking aspirin daily a
      loading dose is recommended; for patients who have not been taking aspirin daily, aspirin
      must be administered as a loading dose. Patients continue to take aspirin indefinitely to
      reduce the risk of thrombosis.

      The main study is the PLATINUM Workhorse Randomized Controlled Trial, which is registered
      under NCT00823212. The clinical protocol includes two companion sub-trials with smaller
      vessels (PLATINUM SV) and longer lesions (PLATINUM LL) plus a Pharmacokinetics sub-trial
      (PLATINUM PK). The three sub-trials are registered under separate NCT numbers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>12-month post index procedure</time_frame>
    <description>Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>30 days</time_frame>
    <description>TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>6 months</time_frame>
    <description>TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>12 months</time_frame>
    <description>TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>30 days</time_frame>
    <description>TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>6 months</time_frame>
    <description>TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>12 months</time_frame>
    <description>TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) Related to the Target Vessel</measure>
    <time_frame>30 days</time_frame>
    <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) Related to the Target Vessel</measure>
    <time_frame>6 months</time_frame>
    <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) Related to the Target Vessel</measure>
    <time_frame>12 months</time_frame>
    <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death Related to the Target Vessel</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death Related to the Target Vessel</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death Related to the Target Vessel</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-cardiac Death</measure>
    <time_frame>30 Days</time_frame>
    <description>Defined as a death not due to cardiac causes (see definition of cardiac death above)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-cardiac Death</measure>
    <time_frame>6 Months</time_frame>
    <description>Defined as a death not due to cardiac causes (see definition of cardiac death above)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-cardiac Death</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as a death not due to cardiac causes (see definition of cardiac death above)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death or Myocardial Infarction (MI)</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death or Myocardial Infarction (MI)</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death or Myocardial Infarction (MI)</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death or Myocardial Infarction (MI)</measure>
    <time_frame>30 days</time_frame>
    <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death or Myocardial Infarction (MI)</measure>
    <time_frame>6 months</time_frame>
    <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death or Myocardial Infarction (MI)</measure>
    <time_frame>12 months</time_frame>
    <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>30 days</time_frame>
    <description>Target lesion revascularization is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>6 months</time_frame>
    <description>TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>12 months</time_frame>
    <description>TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>30 days</time_frame>
    <description>Target vessel revascularization is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>6 months</time_frame>
    <description>TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>12 months</time_frame>
    <description>TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition</measure>
    <time_frame>24 hours</time_frame>
    <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition</measure>
    <time_frame>&gt;24 hr-30 days</time_frame>
    <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition</measure>
    <time_frame>&gt;30 days-1 year</time_frame>
    <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR)</measure>
    <time_frame>30 days</time_frame>
    <description>See above for definitions of MI and TVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR)</measure>
    <time_frame>6 months</time_frame>
    <description>See above for definitions of MI and TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR)</measure>
    <time_frame>12 months</time_frame>
    <description>See above for definitions of MI and TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Procedural Success</measure>
    <time_frame>In hospital</time_frame>
    <description>Defined as mean lesion diameter stenosis &lt;30% with visually assessed TIMI 3 flow and without the occurrence of in-hospital myocardial infarction (MI), target vessel revascularization (TVR), or cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Technical Success</measure>
    <time_frame>Acute-At time of index procedure</time_frame>
    <description>Defined as successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization; expressed per stent</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1530</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>PROMUS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who received the PROMUS (XIENCE V) Everolimus-Eluting Coronary Stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROMUS Element</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PROMUS Coronary Stent System</intervention_name>
    <description>PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).</description>
    <arm_group_label>PROMUS</arm_group_label>
    <other_name>XIENCE V</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PROMUS Element Coronary Stent System</intervention_name>
    <description>PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS [XIENCE V] stent).</description>
    <arm_group_label>PROMUS Element</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.</description>
    <arm_group_label>PROMUS</arm_group_label>
    <arm_group_label>PROMUS Element</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thienopyridine</intervention_name>
    <description>Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.</description>
    <arm_group_label>PROMUS</arm_group_label>
    <arm_group_label>PROMUS Element</arm_group_label>
    <other_name>A brand name for clopidogrel is PLAVIX.</other_name>
    <other_name>A brand name for ticlopidine is TICLID.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be at least 18 years of age

          -  Patient (or legal guardian) understands study requirements and treatment procedures
             and provides written informed consent before any study-specific tests or procedures
             are performed

          -  For patients less than 20 years of age enrolled at a Japanese site, patient and
             patient's legal representative must provide written informed consent before any
             study-specific tests or procedures are performed

          -  Patient is eligible for percutaneous coronary intervention (PCI)

          -  Patient has documented stable angina pectoris or documented silent ischemia; or
             unstable angina pectoris

          -  Patient is an acceptable candidate for coronary artery bypass grafting (CABG)

          -  Patient has a left ventricular ejection fraction (LVEF) &gt;=30% as measured within 30
             days prior to enrollment

          -  Patient is willing to comply with all protocol-required follow-up evaluations

        Angiographic Inclusion Criteria (visual estimate):

        - Target lesion must be a de novo lesion located in a native coronary artery with a
        visually estimated reference vessel diameter (RVD) &gt;=2.50 mm and &lt;=4.25 mm. Target lesion
        length must measure (by visual estimate) &lt;=24 mm. Target lesion must be in a major coronary
        artery or branch with visually estimated stenosis &gt;=50% and &lt;100% with Thrombolysis in
        Myocardial Infarction (TIMI) flow &gt;1.

        Exclusion Criteria:

          -  Patient has clinical symptoms and/or electrocardiogram (ECG) changes consistent with
             acute myocardial infarction (MI)

          -  Patient has had a known diagnosis of recent MI (ie, within 72 hours prior to index
             procedure) and has elevated enzymes at time of index procedure as follows.

               -  Patients are excluded if any of the following criteria are met at time of the
                  index procedure.

                    -  If creatine kinase-myoglobin band (CK-MB) &gt;2× upper limit of normal (ULN),
                       the patient is excluded regardless of CK Total.

                    -  If CK-MB is 1-2× ULN, the patient is excluded if the CK Total is &gt;2× ULN.

               -  If CK Total/CK MB are not used and Troponin is, patients are excluded if the
                  following criterion is met at time of index procedure.

                    -  Troponin &gt;1× ULN with at least one of the following.

                         -  Patient has ischemic symptoms and ECG changes indicative of ongoing
                            ischemia (eg, &gt;1 mm ST segment elevation or depression in consecutive
                            leads or new left bundle branch block [LBBB]);

                         -  Development of pathological Q waves in the ECG; or

                         -  Imaging evidence of new loss of viable myocardium or new regional wall
                            motion abnormality.

        Note: For patients with unstable angina or patients who have had a recent MI, CK Total/CK
        MB (or Troponin if CK Total/CK MB are not used) must be documented prior to
        enrolling/randomizing the patient.

          -  Patient has received an organ transplant or is on a waiting list for an organ
             transplant

          -  Patient is receiving or scheduled to receive chemotherapy within 30 days before or
             after index procedure

          -  Patient is receiving oral or intravenous immunosuppressive therapy (ie, inhaled
             steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune
             disease (eg, human immunodeficiency virus, systemic lupus erythematosus, but not
             including diabetes mellitus)

          -  Patient is receiving chronic (&gt;=72 hours) anticoagulation therapy (eg, heparin,
             coumadin) for indications other than acute coronary syndrome

          -  Patient has platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3

          -  Patient has white blood cell (WBC) count &lt;3,000 cells/mm3

          -  Patient has documented or suspected liver disease, including laboratory evidence of
             hepatitis

          -  Patient is on dialysis or has known renal insufficiency (ie, estimated creatinine
             clearance &lt;50 ml/min by the Cockcroft Gault formula, or [(140-age)*lean body weight
             (in kg)]/[plasma creatinine (mg/dl)*72])

          -  Patient has history of bleeding diathesis or coagulopathy or will refuse blood
             transfusions

          -  Patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA)
             within past 6 months, or has any permanent neurologic defect that may cause
             non-compliance with the protocol

          -  Target vessel(s) or side branch has been treated with any type of PCI (eg, balloon
             angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to index
             procedure

          -  Target vessel(s) has been treated within 10 mm proximal or distal to target lesion (by
             visual estimate) with any type of PCI (eg, balloon angioplasty, stent, cutting
             balloon, atherectomy) at any time prior to index procedure

          -  Non-target vessel or side branch has been treated with any type of PCI (eg, balloon
             angioplasty, stent, cutting balloon, atherectomy) within 24 hours prior to index
             procedure

          -  Planned or actual target vessel(s) treatment with an unapproved device, directional or
             rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction
             catheter immediately prior to stent placement

          -  Planned PCI or CABG after index procedure

          -  Patient previously treated at any time with coronary intravascular brachytherapy

          -  Patient has a known allergy to the study stent system or protocol-required concomitant
             medications (eg, stainless steel, platinum, cobalt, chromium, nickel, tungsten,
             acrylic, fluoropolymers, everolimus, thienopyridines, aspirin, contrast) that cannot
             be adequately premedicated

          -  Patient has active peptic ulcer or active gastrointestinal (GI) bleeding

          -  Patient has one of the following.

               -  Other serious medical illness (eg, cancer, congestive heart failure) that may
                  reduce life expectancy to less than 24 months

               -  Current problems with substance abuse (eg, alcohol, cocaine, heroin, etc.)

               -  Planned procedure that may cause non-compliance with protocol or confound data
                  interpretation

          -  Patient is participating in another investigational drug or device clinical trial that
             has not reached its primary endpoint

          -  Patient intends to participate in another investigational drug or device clinical
             trial within 12 months after index procedure

          -  Patient with known intention to procreate within 12 months after index procedure
             (Women of child-bearing potential who are sexually active must agree to use a reliable
             method of contraception from the time of screening through 12 months after the index
             procedure.)

          -  Patient is a woman who is pregnant or nursing (A pregnancy test must be performed
             within 7 days prior to the index procedure in women of child-bearing potential)

          -  Patient has more than 2 target lesions, or more than 1 target lesion and 1 non-target
             lesion, which will be treated during the index procedure

        Angiographic Exclusion Criteria (visual estimate):

          -  Target lesion meets any of the following criteria:

               -  Aorto-ostial location (ie, lesion located within 5 mm of ostium by visual
                  estimate)

               -  Left main location

               -  Located within 5 mm of origin of the left anterior descending (LAD) coronary
                  artery or left circumflex (LCX) coronary artery by visual estimate

               -  Located within a saphenous vein graft or arterial graft

               -  Will be accessed via a saphenous vein graft or arterial graft

               -  Involves a side branch &gt;=2.0 mm in diameter by visual estimate

               -  Involves a clinically significant side branch &lt;2.0 mm in diameter by visual
                  estimate that has a clinically significant stenosis at the ostium

               -  TIMI flow 0 (total occlusion) or TIMI flow 1 prior to wire crossing

               -  Excessive tortuosity proximal to or within the lesion

               -  Extreme angulation proximal to or within the lesion

               -  Target lesion and/or target vessel proximal to the target lesion is moderately to
                  severely calcified by visual estimate

               -  Restenotic from previous intervention

               -  Thrombus, or possible thrombus, present in target vessel

          -  Non-target lesion to be treated during the index procedure meets any of the following
             criteria:

               -  Located within the target vessel

               -  Located within a bypass graft (venous or arterial)

               -  Left main location

               -  Chronic total occlusion

               -  Involves a complex bifurcation (eg, bifurcations requiring treatment with more
                  than 1 stent)

               -  Restenotic from previous intervention

          -  Patient has unprotected left main coronary artery disease (&gt;50% diameter stenosis)

          -  Patient has protected left main coronary artery disease and a target lesion in the LAD
             or LCX

          -  Patient has an additional clinically significant lesion(s) in target vessel for which
             an intervention within 12 months after the index procedure is likely to be required

          -  Patient has 2 target lesions in the same vessel that are separated by less than 15 mm
             (by visual estimate) Note: Multiple focal stenoses will be considered as a single
             lesion if they can be completely covered with 1 stent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter M Maurer, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baptist Medical Center Princeton</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Good Samaritan Regional Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bakersfield Memorial Hospital</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alvarado Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Denver Cardiology Associates, PC</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of the Rockies (Loveland)</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediQuest Research Group Inc. at Munroe Regional Medical Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Memorial Hospital</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of Central Georgia</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University Memorial Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krannert Institute of Cardiology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital and St. Mary's Healthcare</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Adventist Hospital</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesys Regional Medical Center</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospitals</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Hospital</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Duluth Clinic Regional Heart Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Foundation</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital / Mid America Heart Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Heart Institute</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper Hospital/University Medical Center</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady of Lourdes Medical Center</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaleida Health</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moses H. Cone Memorial Hospital/LeBauer Cardiovascular Research Foundation</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Medical Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lindner Center for Research and Education at The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Health Research and Innovation Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Firelands Regional Medical Center</name>
      <address>
        <city>Sandusky</city>
        <state>Ohio</state>
        <zip>44870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy St. Vincent Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Institute for Medical Research</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health at Harrisburg Hospital</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sisters of Charity Providence Hospital</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson-Madison County General Hospital</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Memorial Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Hospital of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Heart &amp; Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Episcopal Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Texsan Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Mother Frances Health System</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynchburg General Hospital</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Health &amp; Services - Washington</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspirus Heart and Vascular Institute - Research and Education</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <zip>54401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Queensland</city>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhauas AKH</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>B-2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skejby Sygehus</name>
      <address>
        <city>Aarhus</city>
        <zip>D-8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Besancon</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique St. Augustin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Cardiovasculaire - Paris Sud / Institut Hospitalier Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Millenaire</name>
      <address>
        <city>Montpellier</city>
        <zip>34960</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hopital Universitaire Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-und Diabeteszentrum Nordrhein-Westfalen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH</name>
      <address>
        <city>Bad Segeberg</city>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Charite Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitat Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Universitat Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japan Community Health Care Organization Hokkaido Hospital</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Kamakura-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohama-City Eastern Hospital</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakakibara Heart Institute, Japan Research Promotion Society for Cardiovascular Diseases</name>
      <address>
        <city>Fuchu-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teikyo University Hospital</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Ohashi Medical Center</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cardiovascular Institute Hospital</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakurabashi Watanabe Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P. Stradins University Hospital</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarawak General Hospital</name>
      <address>
        <city>Kota Samarahan</city>
        <state>Sarawak</state>
        <zip>94300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jantung Negara</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4818CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catherina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Otahuhu</city>
        <state>Auckland</state>
        <zip>1640</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ascot Angiography</name>
      <address>
        <city>Auckland</city>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Hospital</name>
      <address>
        <city>Wroklaw</city>
        <zip>50-891</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital De Santa Cruz</name>
      <address>
        <city>Carnaxide</city>
        <zip>2799-532</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>168752</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guys and St. Thomas NHS Foundation Trust St. Thomas Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <state>England</state>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Infirmary Oxford II</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <state>Ireland</state>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Clydebank</city>
        <zip>G81 4HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Latvia</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Singapore</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Italy</country>
    <country>Spain</country>
  </removed_countries>
  <results_reference>
    <citation>Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Allocco DJ, Dawkins KD; PLATINUM Trial Investigators. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol. 2011 Apr 19;57(16):1700-8. doi: 10.1016/j.jacc.2011.02.016. Epub 2011 Apr 4.</citation>
    <PMID>21470815</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2009</study_first_posted>
  <results_first_submitted>December 21, 2011</results_first_submitted>
  <results_first_submitted_qc>December 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2012</results_first_posted>
  <disposition_first_submitted>November 10, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>November 10, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 16, 2010</disposition_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug-eluting stents</keyword>
  <keyword>DES</keyword>
  <keyword>atherosclerotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Primary endpoint data uploaded.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment of 1,532 patients was planned; 1,530 patients (762 PROMUS and 768 PROMUS Element) were enrolled and randomized at 132 clinical sites from January 27, 2009 to September 4, 2009. Of these, 788 patients were from the USA, 562 from Europe, 124 from Japan, and 56 from the Asia-Pacific region excluding Japan.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PROMUS</title>
          <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
        </group>
        <group group_id="P2">
          <title>PROMUS Element</title>
          <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="762"/>
                <participants group_id="P2" count="768"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="727">12-month follow-up</participants>
                <participants group_id="P2" count="735">12-month follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incarcerated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed 12-month visit</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PROMUS</title>
          <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
        </group>
        <group group_id="B2">
          <title>PROMUS Element</title>
          <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="762"/>
            <count group_id="B2" value="768"/>
            <count group_id="B3" value="1530"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="413"/>
                    <measurement group_id="B2" value="377"/>
                    <measurement group_id="B3" value="790"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="349"/>
                    <measurement group_id="B2" value="391"/>
                    <measurement group_id="B3" value="740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.11" spread="10.28"/>
                    <measurement group_id="B2" value="63.99" spread="10.27"/>
                    <measurement group_id="B3" value="63.55" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="438"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="542"/>
                    <measurement group_id="B2" value="550"/>
                    <measurement group_id="B3" value="1092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>The same participant may be included in more than one category therefore the number of participants for this baseline measure does not equal the total number of participants in the group.</description>
          <units>participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="644"/>
                    <measurement group_id="B2" value="650"/>
                    <measurement group_id="B3" value="1294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black of African heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maori</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Disclosed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="396"/>
                    <measurement group_id="B2" value="392"/>
                    <measurement group_id="B3" value="788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                    <measurement group_id="B2" value="286"/>
                    <measurement group_id="B3" value="562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacifica</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac History</title>
          <description>The same participant may be included in more than one category therefore the number of participants for this baseline measure does not equal the total number of participants in the group.</description>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Previous Percutaneous Coronary Intervention (PCI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous Coronary Artery Bypass Graft (CABG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous Myocardial Infarction (MI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congestive Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Angina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="463"/>
                    <measurement group_id="B2" value="474"/>
                    <measurement group_id="B3" value="937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unstable Angina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Silent Ischemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac History-Ejection Fraction</title>
          <units>Percent Ejection Fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.04" spread="9.54"/>
                    <measurement group_id="B2" value="59.53" spread="10.07"/>
                    <measurement group_id="B3" value="59.29" spread="9.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac Risk Factor</title>
          <description>The same participant may be included in more than one category therefore the number of participants for this baseline measure does not equal the total number of participants in the group.</description>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Smoking, Ever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="448"/>
                    <measurement group_id="B2" value="493"/>
                    <measurement group_id="B3" value="941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically Treated Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperlipidemia Requiring Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="579"/>
                    <measurement group_id="B2" value="598"/>
                    <measurement group_id="B3" value="1177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension Requiring Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="558"/>
                    <measurement group_id="B2" value="544"/>
                    <measurement group_id="B3" value="1102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family History of Coronary Artery Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="401"/>
                    <measurement group_id="B2" value="392"/>
                    <measurement group_id="B3" value="793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbidities</title>
          <description>The same participant may be included in more than one category therefore the number of participants for this baseline measure does not equal the total number of participants in the group.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History of Peripheral Vascular Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Transient Ischemic Attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Cerebrovascular Accident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Renal Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Gastrointestinal Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristic: Target Lesion Vessel</title>
          <description>Reported per lesion. The same participant may have been treated for &gt;1 lesion and therefore may be included in more than one category. Thus, the total number of lesions for this baseline measure does not equal the total number of participants in the group.</description>
          <units>Lesion</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Left Anterior Descending Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="354"/>
                    <measurement group_id="B2" value="357"/>
                    <measurement group_id="B3" value="711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Circumflex Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Coronary Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="268"/>
                    <measurement group_id="B2" value="273"/>
                    <measurement group_id="B3" value="541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristic: Lesion Location</title>
          <description>Reported per lesion. The same participant may have been treated for &gt;1 lesion and therefore may be included in more than one category. Thus, the total number of lesions for this baseline measure does not equal the total number of participants in the group.</description>
          <units>Lesions</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ostial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="338"/>
                    <measurement group_id="B2" value="348"/>
                    <measurement group_id="B3" value="686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="401"/>
                    <measurement group_id="B2" value="387"/>
                    <measurement group_id="B3" value="788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristics</title>
          <units>Millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Reference Vessel Diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.63" spread="0.49"/>
                    <measurement group_id="B2" value="2.67" spread="0.49"/>
                    <measurement group_id="B3" value="2.65" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimum Lumen Diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.74" spread="0.34"/>
                    <measurement group_id="B2" value="0.75" spread="0.35"/>
                    <measurement group_id="B3" value="0.75" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lesion Length</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.50" spread="5.51"/>
                    <measurement group_id="B2" value="12.95" spread="5.74"/>
                    <measurement group_id="B3" value="12.72" spread="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristic-Percent Diameter Stenosis</title>
          <units>Percent Diameter Stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.90" spread="11.47"/>
                    <measurement group_id="B2" value="71.81" spread="11.46"/>
                    <measurement group_id="B3" value="71.86" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristics</title>
          <description>Reported per lesion. The same participant may have been treated for &gt;1 lesion and therefore may be included in more than one category. Thus, the total number of lesions for this baseline measure does not equal the total number of participants in the group.</description>
          <units>Lesions</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Eccentric Lesion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="454"/>
                    <measurement group_id="B2" value="477"/>
                    <measurement group_id="B3" value="931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 45 Degree Bend</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 90 Degree Bend</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tortuosity, any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcification, any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Occlusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bifurcation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristics: American College of Cardiology (ACC)/American Heart Association (AHA) Class</title>
          <description>Type A: minimally complex, readily accessible, non-angulated, smooth contour, little to no calcification, less than totally occlusive, not ostial in location, no major side branch involvement, absence of thrombus.
Type B: moderately complex, eccentric, moderate tortuosity and angulation, moderate or heavy calcification, total occlusion &lt; 3 months old, ostial location with presence of thrombus.
Type C: severely complex, diffuse, excessive tortuosity and angulation, total occlusions &gt; 3 months old, degenerated vein grafts,friable lesions</description>
          <units>Lesions</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Type A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type B1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type B2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="361"/>
                    <measurement group_id="B2" value="378"/>
                    <measurement group_id="B3" value="739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="179"/>
                    <measurement group_id="B3" value="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristic - Pre-Procedure Thrombolysis In Myocardial Infarction (TIMI) Flow</title>
          <description>TIMI 0 - No perfusion TIMI 1 - Penetration with minimal perfusion TIMI 2 - Partial perfusion TIMI 3 - Complete perfusion A participant may be treated for &gt;1 lesion, therefore the number of lesions for this baseline measure does not equal the total number of participants in the group.</description>
          <units>Lesion</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>TIMI 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="808"/>
                    <measurement group_id="B2" value="818"/>
                    <measurement group_id="B3" value="1626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Target Lesion Failure (TLF)</title>
        <description>Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non–Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
        <time_frame>12-month post index procedure</time_frame>
        <population>The primary analysis set for the non-inferiority testing of the primary endpoint, 12-month TLF, is the per-protocol analysis set. All randomized participants who received their assigned treatment are included in the per-protocol analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>PROMUS everolimus-eluting stent (EES) implanted using standard percutaneous coronary intervention (PCI) technique</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>PROMUS Element everolimus-eluting stent (EES) implanted using standard percutaneous coronary intervention (PCI) technique</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Failure (TLF)</title>
          <description>Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non–Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
          <population>The primary analysis set for the non-inferiority testing of the primary endpoint, 12-month TLF, is the per-protocol analysis set. All randomized participants who received their assigned treatment are included in the per-protocol analysis set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="714"/>
                <count group_id="O2" value="731"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Study had 89% statistical power to demonstrate non-inferiority for target lesion failure (TLF, accounting for an expected 1-year attrition rate of 5%), assuming a 1-year TLF rate of 5.5% for both stents.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A 2-group Farrington-Manning test was used to test the 1-sided hypothesis of non-inferiority in differences with a non-inferiority margin of 3.5%. A p value &lt;0.05 would indicate non-inferiority and correspond to the upper limit of the 1-sided 95% confidence interval of the difference not exceeding 3.5%.</non_inferiority_desc>
            <p_value>0.001</p_value>
            <method>Farrington-Manning test</method>
            <param_type>Difference in percent of participants</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>2.13</ci_upper_limit>
            <estimate_desc>The standard error for the difference was estimated according to the Farrington-Manning test.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Failure (TLF)</title>
        <description>TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non–Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
        <time_frame>30 days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Failure (TLF)</title>
          <description>TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non–Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="761"/>
                <count group_id="O2" value="766"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Failure (TLF)</title>
        <description>TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non–Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
        <time_frame>6 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Failure (TLF)</title>
          <description>TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non–Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="756"/>
                <count group_id="O2" value="763"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Failure (TLF)</title>
        <description>TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non–Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
        <time_frame>12 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Failure (TLF)</title>
          <description>TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non–Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="727"/>
                <count group_id="O2" value="742"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure (TVF)</title>
        <description>TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non–Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
        <time_frame>30 days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure (TVF)</title>
          <description>TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non–Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="761"/>
                <count group_id="O2" value="766"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure (TVF)</title>
        <description>TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non–Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
        <time_frame>6 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure (TVF)</title>
          <description>TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non–Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="756"/>
                <count group_id="O2" value="763"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure (TVF)</title>
        <description>TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non–Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
        <time_frame>12 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure (TVF)</title>
          <description>TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non–Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="727"/>
                <count group_id="O2" value="742"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI) Related to the Target Vessel</title>
        <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
        <time_frame>30 days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction (MI) Related to the Target Vessel</title>
          <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="761"/>
                <count group_id="O2" value="766"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI) Related to the Target Vessel</title>
        <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
        <time_frame>6 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction (MI) Related to the Target Vessel</title>
          <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="759"/>
                <count group_id="O2" value="765"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI) Related to the Target Vessel</title>
        <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
        <time_frame>12 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction (MI) Related to the Target Vessel</title>
          <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="732"/>
                <count group_id="O2" value="745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>30 days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="761"/>
                <count group_id="O2" value="766"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>6 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="759"/>
                <count group_id="O2" value="765"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>12 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="732"/>
                <count group_id="O2" value="745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death Related to the Target Vessel</title>
        <description>Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded</description>
        <time_frame>30 days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death Related to the Target Vessel</title>
          <description>Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="761"/>
                <count group_id="O2" value="766"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death Related to the Target Vessel</title>
        <description>Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded</description>
        <time_frame>6 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death Related to the Target Vessel</title>
          <description>Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="759"/>
                <count group_id="O2" value="765"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death Related to the Target Vessel</title>
        <description>Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded</description>
        <time_frame>12 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death Related to the Target Vessel</title>
          <description>Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="732"/>
                <count group_id="O2" value="745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-cardiac Death</title>
        <description>Defined as a death not due to cardiac causes (see definition of cardiac death above)</description>
        <time_frame>30 Days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Non-cardiac Death</title>
          <description>Defined as a death not due to cardiac causes (see definition of cardiac death above)</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="761"/>
                <count group_id="O2" value="766"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-cardiac Death</title>
        <description>Defined as a death not due to cardiac causes (see definition of cardiac death above)</description>
        <time_frame>6 Months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Non-cardiac Death</title>
          <description>Defined as a death not due to cardiac causes (see definition of cardiac death above)</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="759"/>
                <count group_id="O2" value="765"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-cardiac Death</title>
        <description>Defined as a death not due to cardiac causes (see definition of cardiac death above)</description>
        <time_frame>12 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Non-cardiac Death</title>
          <description>Defined as a death not due to cardiac causes (see definition of cardiac death above)</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="732"/>
                <count group_id="O2" value="745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death or Myocardial Infarction (MI)</title>
        <description>Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above</description>
        <time_frame>30 days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death or Myocardial Infarction (MI)</title>
          <description>Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="761"/>
                <count group_id="O2" value="766"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death or Myocardial Infarction (MI)</title>
        <description>Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above</description>
        <time_frame>6 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death or Myocardial Infarction (MI)</title>
          <description>Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="759"/>
                <count group_id="O2" value="765"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death or Myocardial Infarction (MI)</title>
        <description>Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above</description>
        <time_frame>12 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death or Myocardial Infarction (MI)</title>
          <description>Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="732"/>
                <count group_id="O2" value="745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death or Myocardial Infarction (MI)</title>
        <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
        <time_frame>30 days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>All Death or Myocardial Infarction (MI)</title>
          <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="761"/>
                <count group_id="O2" value="766"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death or Myocardial Infarction (MI)</title>
        <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
        <time_frame>6 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>All Death or Myocardial Infarction (MI)</title>
          <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="759"/>
                <count group_id="O2" value="765"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death or Myocardial Infarction (MI)</title>
        <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
        <time_frame>12 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>All Death or Myocardial Infarction (MI)</title>
          <description>Development of new Q-waves in ≥2 leads lasting ≥0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) &gt;3x normal (peri-percutaneous coronary intervention [PCI]) or &gt;2x normal (spontaneous) with elevated CK-MB, or troponin &gt;3x normal (peri-PCI) or &gt;2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin &gt;5x normal</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="732"/>
                <count group_id="O2" value="735"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR)</title>
        <description>Target lesion revascularization is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
        <time_frame>30 days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR)</title>
          <description>Target lesion revascularization is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="761"/>
                <count group_id="O2" value="766"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR)</title>
        <description>TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
        <time_frame>6 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR)</title>
          <description>TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="759"/>
                <count group_id="O2" value="765"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR)</title>
        <description>TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
        <time_frame>12 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR)</title>
          <description>TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="732"/>
                <count group_id="O2" value="745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR)</title>
        <description>Target vessel revascularization is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
        <time_frame>30 days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR)</title>
          <description>Target vessel revascularization is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="761"/>
                <count group_id="O2" value="766"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR)</title>
        <description>TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
        <time_frame>6 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR)</title>
          <description>TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="759"/>
                <count group_id="O2" value="765"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR)</title>
        <description>TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
        <time_frame>12 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR)</title>
          <description>TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="732"/>
                <count group_id="O2" value="745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition</title>
        <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).</description>
        <time_frame>24 hours</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition</title>
          <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="762"/>
                <count group_id="O2" value="768"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition</title>
        <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).</description>
        <time_frame>&gt;24 hr-30 days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition</title>
          <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="762"/>
                <count group_id="O2" value="766"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition</title>
        <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).</description>
        <time_frame>&gt;30 days-1 year</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition</title>
          <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="760"/>
                <count group_id="O2" value="764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR)</title>
        <description>See above for definitions of MI and TVR</description>
        <time_frame>30 days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR)</title>
          <description>See above for definitions of MI and TVR</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="761"/>
                <count group_id="O2" value="766"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR)</title>
        <description>See above for definitions of MI and TVR.</description>
        <time_frame>6 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR)</title>
          <description>See above for definitions of MI and TVR.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="759"/>
                <count group_id="O2" value="765"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR)</title>
        <description>See above for definitions of MI and TVR.</description>
        <time_frame>12 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR)</title>
          <description>See above for definitions of MI and TVR.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="732"/>
                <count group_id="O2" value="745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Procedural Success</title>
        <description>Defined as mean lesion diameter stenosis &lt;30% with visually assessed TIMI 3 flow and without the occurrence of in-hospital myocardial infarction (MI), target vessel revascularization (TVR), or cardiac death</description>
        <time_frame>In hospital</time_frame>
        <population>Analysis was intention to treat (all patients in study).</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Procedural Success</title>
          <description>Defined as mean lesion diameter stenosis &lt;30% with visually assessed TIMI 3 flow and without the occurrence of in-hospital myocardial infarction (MI), target vessel revascularization (TVR), or cardiac death</description>
          <population>Analysis was intention to treat (all patients in study).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="761"/>
                <count group_id="O2" value="767"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2"/>
                    <measurement group_id="O2" value="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Technical Success</title>
        <description>Defined as successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization; expressed per stent</description>
        <time_frame>Acute-At time of index procedure</time_frame>
        <population>Analysis was intention to treat (all patients in the study).</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS</title>
            <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
          </group>
          <group group_id="O2">
            <title>PROMUS Element</title>
            <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Technical Success</title>
          <description>Defined as successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization; expressed per stent</description>
          <population>Analysis was intention to treat (all patients in the study).</population>
          <units>percentage of stents</units>
          <param>Number</param>
          <units_analyzed>Stents</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="762"/>
                <count group_id="O2" value="768"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Stents</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="894"/>
                <count group_id="O2" value="887"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8"/>
                    <measurement group_id="O2" value="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Site reported other adverse events were collected through 365 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PROMUS</title>
          <description>Participants randomized to treatment with PROMUS everolimus-eluting stent (control device)</description>
        </group>
        <group group_id="E2">
          <title>PROMUS Element</title>
          <description>Participants randomized to treatment with PROMUS Element everolimus-eluting stent (investigational device)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="237" subjects_at_risk="762"/>
                <counts group_id="E2" subjects_affected="238" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="762"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Hypercoagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="39" subjects_affected="35" subjects_at_risk="762"/>
                <counts group_id="E2" events="48" subjects_affected="44" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="762"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="762"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="762"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="762"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="762"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="762"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Coronary artery perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Dressler's syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Ischemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Sinus bradychardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal arteriovenous malformation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="762"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Inguinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Mesenteric artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Cholitis ischaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="37" subjects_affected="32" subjects_at_risk="762"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="762"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Catheter sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Fungaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstruction airways disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Pneomonia haemophilus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="762"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Spinal cord injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Traumatic haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Cardiac stress test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST segment elevation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Diabetes ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Athralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Pseudarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Spinal ligament ossification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Acute leukemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Angiomyolipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Benign bone neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Benign renal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="762"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="762"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Bladder tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="762"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="762"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Hyperventillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Intermittant claudication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="762"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Arterial stenosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="762"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="762"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="762"/>
                <counts group_id="E2" subjects_affected="197" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="86" subjects_affected="79" subjects_at_risk="762"/>
                <counts group_id="E2" events="73" subjects_affected="65" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="762"/>
                <counts group_id="E2" events="41" subjects_affected="41" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="762"/>
                <counts group_id="E2" events="44" subjects_affected="40" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="762"/>
                <counts group_id="E2" events="42" subjects_affected="41" subjects_at_risk="768"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="59" subjects_affected="53" subjects_at_risk="762"/>
                <counts group_id="E2" events="53" subjects_affected="49" subjects_at_risk="768"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Principal Investigator shall have the right to publish the results, provided that before publishing, the PI shall submit copies of any proposed publication or presentation to Sponsor for review at least 45 days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any confidential information or other proprietary information of Sponsor from the proposed publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ruth Starzyk, PhD</name_or_title>
      <organization>Boston Scientific Corporation</organization>
      <phone>508-683-6577</phone>
      <email>ruth.starzyk@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

